Use of transmembrane activator, calcium modulator and taci-immunoglobulin fusion proteins for manufacture of a medicament for treating sjogren's syndrome

摘要

Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.